CXCR2 and head and neck squamous cell carcinoma: Retrospective analyses of the radio(chemo)therapy TCGA HNSCC subcohort and an in-house radio(chemo)therapy HNSCC cohort showed that elevated expression of CXCR2 and/or its ligands associates with impaired treatment outcome.